EA202190463A1 - Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов - Google Patents

Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Info

Publication number
EA202190463A1
EA202190463A1 EA202190463A EA202190463A EA202190463A1 EA 202190463 A1 EA202190463 A1 EA 202190463A1 EA 202190463 A EA202190463 A EA 202190463A EA 202190463 A EA202190463 A EA 202190463A EA 202190463 A1 EA202190463 A1 EA 202190463A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
disease
ccr3
function
inhibitors
Prior art date
Application number
EA202190463A
Other languages
English (en)
Inventor
Стивен П. Брайтуэйт
С. Сакура Минами
Кароли Николич
Санкет В. Ридж
Арнод Е. Дж. Тейчерт
Original Assignee
Алкахест, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алкахест, Инк. filed Critical Алкахест, Инк.
Publication of EA202190463A1 publication Critical patent/EA202190463A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены способы облегчения нейродегенеративного заболевания с применением CCR3-модулирующих агентов. Предложенные способы включают введение субъекту терапевтически эффективного количества CCR3-модулирующего агента с сопутствующим улучшением познавательной функции, двигательной функции или другой функции, нарушенной вследствие нейродегенеративного заболевания. Когнитивные и двигательные заболевания, при которых когнитивная функция может быть улучшена способами по данному изобретению, включают болезнь Альцгеймера, болезнь Паркинсона, лобно-височную деменцию, болезнь Хантингтона, амиотрофический боковой склероз, рассеянный склероз, глаукому, миотоническую дистрофию, сосудистую деменцию, прогрессирующий надъядерный паралич.
EA202190463A 2018-09-26 2019-09-25 Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов EA202190463A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
EA202190463A1 true EA202190463A1 (ru) 2021-06-29

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190463A EA202190463A1 (ru) 2018-09-26 2019-09-25 Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Country Status (16)

Country Link
EP (1) EP3856195A4 (ru)
JP (1) JP7528065B2 (ru)
KR (1) KR20210065950A (ru)
CN (1) CN112789044A (ru)
AU (1) AU2019346456A1 (ru)
BR (1) BR112021004938A2 (ru)
CA (1) CA3111433A1 (ru)
CL (1) CL2021000724A1 (ru)
CO (1) CO2021003713A2 (ru)
EA (1) EA202190463A1 (ru)
IL (1) IL281578A (ru)
MA (1) MA53743A (ru)
MX (1) MX2021002967A (ru)
SG (1) SG11202102105VA (ru)
TW (1) TW202027752A (ru)
WO (1) WO2020069008A1 (ru)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
PE20150925A1 (es) 2009-04-22 2015-06-14 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN110650740A (zh) * 2017-04-05 2020-01-03 万能溶剂有限公司 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3

Also Published As

Publication number Publication date
KR20210065950A (ko) 2021-06-04
CA3111433A1 (en) 2020-04-02
JP7528065B2 (ja) 2024-08-05
JP2022502441A (ja) 2022-01-11
MX2021002967A (es) 2021-08-11
BR112021004938A2 (pt) 2021-06-01
CL2021000724A1 (es) 2021-10-15
MA53743A (fr) 2022-01-05
IL281578A (en) 2021-05-31
TW202027752A (zh) 2020-08-01
WO2020069008A1 (en) 2020-04-02
EP3856195A1 (en) 2021-08-04
SG11202102105VA (en) 2021-04-29
EP3856195A4 (en) 2022-06-22
CN112789044A (zh) 2021-05-11
AU2019346456A1 (en) 2021-04-15
CO2021003713A2 (es) 2021-04-08

Similar Documents

Publication Publication Date Title
MX2019011988A (es) Metodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3.
WO2018015573A3 (en) Trem2 cleavage modulators and uses thereof
PH12018502028A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
MX2019006645A (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
GEP201706608B (en) 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases
EA201991755A1 (ru) Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
EA201991756A1 (ru) Бисгетероарильные производные в качестве модуляторов агрегации белков
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
MX2019002444A (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
PE20191082A1 (es) Inhibidores de la tirosina quinasa de bruton
JP2019524822A5 (ru)
MX2023012694A (es) 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas.
PH12020551779A1 (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
DK2091942T3 (da) Substituerede pyrazinderivater til anvendelse som en medicin
EA202190463A1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
WO2020092102A3 (en) 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of the m4 muscarinic acetylcholine receptor
EA201992188A1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов
EA201991753A1 (ru) Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
PA8608601A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
BR112022011810A2 (pt) Compostos inibidores de oga
MA54630B1 (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives
NO20084819L (no) Substituerte pyrazinonderivater for anvendelse som en medisin
MX2021007551A (es) Acidos biliares 2-fluorados para el tratamiento de enfermedades neurodegenerativas.
MX2017012239A (es) Metodos y composiciones para la administracion intravenosa de fumaratos para el tratamiento de enfermedades neurologicas.